1. Home
  2. TGTX vs TX Comparison

TGTX vs TX Comparison

Compare TGTX & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$49.93

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Logo Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

TX

Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

HOLD

Current Price

$54.59

Market Cap

9.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
TX
Founded
1993
1961
Country
United States
Luxembourg
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
9.1B
IPO Year
2008
2006

Fundamental Metrics

Financial Performance
Metric
TGTX
TX
Price
$49.93
$54.59
Analyst Decision
Strong Buy
Hold
Analyst Count
5
5
Target Price
$49.80
$37.70
AVG Volume (30 Days)
2.3M
750.9K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
6.31%
EPS Growth
1746.67
N/A
EPS
0.17
N/A
Revenue
$2,785,000.00
N/A
Revenue This Year
$49.08
$9.60
Revenue Next Year
$26.69
$6.66
P/E Ratio
$293.53
$20.15
Revenue Growth
N/A
N/A
52 Week Low
$26.76
$31.44
52 Week High
$59.30
$55.66

Technical Indicators

Market Signals
Indicator
TGTX
TX
Relative Strength Index (RSI) 44.73 74.13
Support Level $45.37 $41.60
Resistance Level $58.08 N/A
Average True Range (ATR) 2.12 1.55
MACD -0.51 0.69
Stochastic Oscillator 38.04 95.34

Price Performance

Historical Comparison
TGTX
TX

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About TX Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.

Share on Social Networks: